Treatment of bipolar disorder

Review of evidence regarding quetiapine and lithium

Terence A. Ketter, Shefali Miller, Bernardo Dell'Osso, Po W. Wang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Lithium, the prototypical mood stabilizer, and quetiapine, a second-generation antipsychotic, are widely used acute and maintenance pharmacotherapies for bipolar disorder. The Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE) study was the first comparative effectiveness assessment of lithium versus quetiapine (in combination with adjunctive personalized treatment), and found no overall significant differences in efficacy and safety/tolerability outcomes between lithium and quetiapine. Completion of Bipolar CHOICE offers a timely opportunity to review the evidence regarding lithium and quetiapine for bipolar disorder. Methods Controlled clinical trials and real-world observational studies that included quetiapine and lithium as monotherapy or as combination therapy were identified by literature search. Selected studies were reviewed in detail. Results Review of the available trials suggested comparable efficacy of quetiapine and lithium in acute mania, and possibly greater efficacy for quetiapine compared with lithium in acute bipolar depression and in prevention of recurrent (particularly depressive) episodes. Combination therapy including quetiapine and lithium was generally more effective than either agent alone in acute mania and bipolar maintenance, although adding lithium to quetiapine did not increase efficacy in acute bipolar depression. Safety data for quetiapine and lithium were consistent with the established profiles of the two treatments. Limitations Limitations include those of the available efficacy and effectiveness trial data. Conclusions Quetiapine and lithium have overlapping but distinctive roles in different phases of bipolar disorder, and further studies of these agents (particularly in combination with one another) are warranted.

Original languageEnglish
Pages (from-to)256-273
Number of pages18
JournalJournal of Affective Disorders
Volume191
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Bipolar Disorder
Lithium
Therapeutics
Quetiapine Fumarate
Maintenance
Safety
Controlled Clinical Trials
Antipsychotic Agents
Observational Studies
Drug Therapy
Health

Keywords

  • Bipolar disorder
  • Lithium
  • Quetiapine
  • Randomized controlled trial
  • Real-world practice

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Treatment of bipolar disorder : Review of evidence regarding quetiapine and lithium. / Ketter, Terence A.; Miller, Shefali; Dell'Osso, Bernardo; Wang, Po W.

In: Journal of Affective Disorders, Vol. 191, 01.02.2016, p. 256-273.

Research output: Contribution to journalArticle

Ketter, Terence A. ; Miller, Shefali ; Dell'Osso, Bernardo ; Wang, Po W. / Treatment of bipolar disorder : Review of evidence regarding quetiapine and lithium. In: Journal of Affective Disorders. 2016 ; Vol. 191. pp. 256-273.
@article{328946cdf9574d72a51cd1a61f076f7e,
title = "Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium",
abstract = "Background Lithium, the prototypical mood stabilizer, and quetiapine, a second-generation antipsychotic, are widely used acute and maintenance pharmacotherapies for bipolar disorder. The Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE) study was the first comparative effectiveness assessment of lithium versus quetiapine (in combination with adjunctive personalized treatment), and found no overall significant differences in efficacy and safety/tolerability outcomes between lithium and quetiapine. Completion of Bipolar CHOICE offers a timely opportunity to review the evidence regarding lithium and quetiapine for bipolar disorder. Methods Controlled clinical trials and real-world observational studies that included quetiapine and lithium as monotherapy or as combination therapy were identified by literature search. Selected studies were reviewed in detail. Results Review of the available trials suggested comparable efficacy of quetiapine and lithium in acute mania, and possibly greater efficacy for quetiapine compared with lithium in acute bipolar depression and in prevention of recurrent (particularly depressive) episodes. Combination therapy including quetiapine and lithium was generally more effective than either agent alone in acute mania and bipolar maintenance, although adding lithium to quetiapine did not increase efficacy in acute bipolar depression. Safety data for quetiapine and lithium were consistent with the established profiles of the two treatments. Limitations Limitations include those of the available efficacy and effectiveness trial data. Conclusions Quetiapine and lithium have overlapping but distinctive roles in different phases of bipolar disorder, and further studies of these agents (particularly in combination with one another) are warranted.",
keywords = "Bipolar disorder, Lithium, Quetiapine, Randomized controlled trial, Real-world practice",
author = "Ketter, {Terence A.} and Shefali Miller and Bernardo Dell'Osso and Wang, {Po W.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.jad.2015.11.002",
language = "English",
volume = "191",
pages = "256--273",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Treatment of bipolar disorder

T2 - Review of evidence regarding quetiapine and lithium

AU - Ketter, Terence A.

AU - Miller, Shefali

AU - Dell'Osso, Bernardo

AU - Wang, Po W.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Lithium, the prototypical mood stabilizer, and quetiapine, a second-generation antipsychotic, are widely used acute and maintenance pharmacotherapies for bipolar disorder. The Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE) study was the first comparative effectiveness assessment of lithium versus quetiapine (in combination with adjunctive personalized treatment), and found no overall significant differences in efficacy and safety/tolerability outcomes between lithium and quetiapine. Completion of Bipolar CHOICE offers a timely opportunity to review the evidence regarding lithium and quetiapine for bipolar disorder. Methods Controlled clinical trials and real-world observational studies that included quetiapine and lithium as monotherapy or as combination therapy were identified by literature search. Selected studies were reviewed in detail. Results Review of the available trials suggested comparable efficacy of quetiapine and lithium in acute mania, and possibly greater efficacy for quetiapine compared with lithium in acute bipolar depression and in prevention of recurrent (particularly depressive) episodes. Combination therapy including quetiapine and lithium was generally more effective than either agent alone in acute mania and bipolar maintenance, although adding lithium to quetiapine did not increase efficacy in acute bipolar depression. Safety data for quetiapine and lithium were consistent with the established profiles of the two treatments. Limitations Limitations include those of the available efficacy and effectiveness trial data. Conclusions Quetiapine and lithium have overlapping but distinctive roles in different phases of bipolar disorder, and further studies of these agents (particularly in combination with one another) are warranted.

AB - Background Lithium, the prototypical mood stabilizer, and quetiapine, a second-generation antipsychotic, are widely used acute and maintenance pharmacotherapies for bipolar disorder. The Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE) study was the first comparative effectiveness assessment of lithium versus quetiapine (in combination with adjunctive personalized treatment), and found no overall significant differences in efficacy and safety/tolerability outcomes between lithium and quetiapine. Completion of Bipolar CHOICE offers a timely opportunity to review the evidence regarding lithium and quetiapine for bipolar disorder. Methods Controlled clinical trials and real-world observational studies that included quetiapine and lithium as monotherapy or as combination therapy were identified by literature search. Selected studies were reviewed in detail. Results Review of the available trials suggested comparable efficacy of quetiapine and lithium in acute mania, and possibly greater efficacy for quetiapine compared with lithium in acute bipolar depression and in prevention of recurrent (particularly depressive) episodes. Combination therapy including quetiapine and lithium was generally more effective than either agent alone in acute mania and bipolar maintenance, although adding lithium to quetiapine did not increase efficacy in acute bipolar depression. Safety data for quetiapine and lithium were consistent with the established profiles of the two treatments. Limitations Limitations include those of the available efficacy and effectiveness trial data. Conclusions Quetiapine and lithium have overlapping but distinctive roles in different phases of bipolar disorder, and further studies of these agents (particularly in combination with one another) are warranted.

KW - Bipolar disorder

KW - Lithium

KW - Quetiapine

KW - Randomized controlled trial

KW - Real-world practice

UR - http://www.scopus.com/inward/record.url?scp=84960929440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960929440&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2015.11.002

DO - 10.1016/j.jad.2015.11.002

M3 - Article

VL - 191

SP - 256

EP - 273

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -